Founded in 2022 by Dr. Gregory Jean-Noel, Oridin Group began with a mission to bridge regulatory precision with operational agility in the pharmaceutical industry. Over two decades later, we continue to support public and private organizations in advancing compliant, life-changing therapies to market.
Our team’s expertise spans from early-phase clinical design to commercial readiness, with a special emphasis on supporting federal programs, submissions to agencies like the FDA and VA, and streamlining compliance for innovative biotech firms entering government partnerships.
Oridin’s consultants have supported over 80 federal-facing pharmaceutical initiatives, including collaborations with NIH, BARDA, and ASPR. Whether managing submissions or improving compliance infrastructure, we operate with the urgency and reliability government projects demand.
Our subject matter experts bring both technical depth and programmatic clarity—capable of transforming ambiguous requirements into timely deliverables. We thrive in highly-regulated, outcomes-driven environments. And when the mission calls for a heroic save, we bring donuts.
0
0
0
0
We work with urgency, but never haste. Oridin’s consultants apply decades of operational experience to complex environments—translating technical, clinical, and regulatory requirements into action plans that federal buyers understand.
And while our team includes FDA veterans and biostats PhDs, we remain unusually approachable. Our clients tell us we’re the only vendor who’s ever made a pre-IND meeting feel like a conversation instead of an interrogation.
As a small and agile firm, we adapt quickly to changing priorities and regulatory expectations. Whether you’re preparing for your first federal audit or navigating a cross-agency clinical trial, Oridin Group brings structure, clarity, and calm.
...And yes, if you need it, we can help translate the CFR into plain English. (Though we reserve the right to charge extra for PowerPoint slides containing actual magic.)
- Contact Us
Reach out for scientifically sound, market-ready guidance—delivered with precision and ingenuity.